{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:49:07Z","timestamp":1774885747852,"version":"3.50.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Compassionate use programs (CUP) for medicines respond to the ethical imperative of providing access to medicines before marketing approval to patients not recruited in trials. The economic impact of clinical trials has previously been investigated. No evidence on the net economic benefit of CUP exists. This research aims to address this information gap by estimating the economic consequences of 11 CUP in Italy conducted between March 2015 and December 2020 from the perspective of public health care system in Italy (National Health Service). Eight programs concern cancer treatments, two refer to spinal muscular atrophy, and one is indicated for multiple sclerosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Since CUP medicines are covered by the industry, the net economic benefit includes: (i) avoided costs of the Standard of Care (SoC) the patients would have received had they not joined the CUP, (ii) costs not covered by the pharmaceutical industry sponsor, but instead sustained by payers, such as those associated with adverse events (only severe side effects resulting in hospitalisation and attributable to CUP medicines), and (iii) costs for combination therapies and diagnostic procedures not used with the SoC. The SoC costing relied on publicly available data. Information on adverse events and diagnostic procedures was retrieved from the CUP and monetized using the relevant fee for episode or service. One CUP was excluded since a SoC was not identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>2,713 patients were treated in the 11 CUP where a SoC was identified. The SoC mean cost per patient ranged from \u20ac11,415 to \u20ac20,299. The total cost of the SoC ranged between \u20ac31.0 and \u20ac55.1 million. The mean cost per patient covered by hospitals hosting CUP was equal to \u20ac1,646, with a total cost of \u20ac4.5 million. The net economic benefit ranged \u20ac26.5 million - \u20ac50.6 million.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite research limitations, this paper illustrates for the first time the net economic impact of CUP from a public payer perspective. It is important to integrate these estimates with the prospective effects of CUP implementation, i.e., the economic value of the comparative benefit profile of medicines used in CUP versus the SoC, including effects from a societal perspective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-021-07255-w","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T10:02:22Z","timestamp":1638612142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The economic impact of compassionate use of medicines"],"prefix":"10.1186","volume":"21","author":[{"given":"Claudio","family":"Jommi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pantellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Stagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Verykiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Cavazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"key":"7255_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/2168479017694848","volume":"51","author":"TA Watson","year":"2017","unstructured":"Watson TA. Global Perspective on Compassionate Use and Expanded Access. Ther Innov Regul Sci. 2017;51:143\u20135.","journal-title":"Ther Innov Regul Sci"},{"key":"7255_CR2","unstructured":"European Parliament. 32004R0726 Regulation (EC) No 726\/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official Journal L136. 2004;1\u201333. http:\/\/data.europa.eu\/eli\/reg\/2004\/726\/oj. Accessed 15 Mar 2021."},{"key":"7255_CR3","unstructured":"European Medicines Agency. Guideline on Compassionate Use of Medicinal Products, Pursuant to Article 83 of Regulation (Ec) No 726\/2004. European Medicines Agency. London, UK, 2007;1-8. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compassionate-use. Accessed 15 Mar 2021."},{"issue":"4","key":"7255_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.5582\/irdr.2016.01054","volume":"5","author":"G Balasubramanian","year":"2016","unstructured":"Balasubramanian G, Morampudi S, Chhabra P, Gowda A, Zomorodi B. An overview of Compassionate Use Programs in the European Union member states. Intractable Rare Dis Res. 2016;5(4):244\u2013254.","journal-title":"Intractable Rare Dis Res"},{"key":"7255_CR5","unstructured":"Ministero della Salute. DECRETO 7 settembre 2017 Disciplina dell\u2019uso terapeutico di medicinale sottoposto a sperimentazione clinica (17A07305) (GU Serie Generale n.256 del 02-11-2017). https:\/\/www.gazzettaufficiale.it\/eli\/id\/2017\/11\/02\/17A07305\/SG. Accessed 15 Mar 2021."},{"key":"7255_CR6","doi-asserted-by":"crossref","unstructured":"Polak T, Uyl-de Groot CA, Van Rosmalen J. PNS410 Data from expanded access programs: treatment first, collection second. An overview of FDA and EMA regulatory approvals. Value in Health. 2019;22 Suppl 3:835.","DOI":"10.1016\/j.jval.2019.09.2310"},{"key":"7255_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12910-019-0420-8","volume":"20","author":"EM Bunnik","year":"2019","unstructured":"Bunnik, EM, Aarts, N. What do patients with unmet medical needs want? A qualitative study of patients\u2019 views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. BMC Medical Ethics. 2019;20:80.","journal-title":"BMC Medical Ethics"},{"key":"7255_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11673-021-10090-7","volume":"18","author":"EM Bunnik","year":"2021","unstructured":"Bunnik, EM, Aarts, N. The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods Study of Physicians\u2019 Views and Experiences in The Netherlands. Bioethical Inquiry. 2021;18:319\u2013334.","journal-title":"Bioethical Inquiry"},{"issue":"11","key":"7255_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/medethics-2016-103917","volume":"44","author":"AL Caplan","year":"2018","unstructured":"Caplan AL, Teagarden JR, Kearns L, Bateman-House AS, Mitchell E, Arawi T, et al. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials. J Med Ethics. 2018;44(11):761\u2013767.","journal-title":"J Med Ethics"},{"key":"7255_CR10","unstructured":"Armeni P, Bertolani A, Borsoi L, Costa F. La spesa sanitaria: composizione ed evoluzione. In Cergas Bocconi (ed.). Rapporto Oasi 2020. Egea, Milano. https:\/\/www.cergas.unibocconi.eu\/observatories\/oasi_\/oasi-report-2020. Accessed 14 Oct 2021."},{"key":"7255_CR11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-319-12169-7_8","volume-title":"Zaheer-Ud-Din Babar editor, Pharmaceutical Prices in the 21st Century","author":"C Jommi","year":"2015","unstructured":"Jommi C, Minghetti P. Pharmaceutical Pricing Policies in Italy, in Zaheer-Ud-Din Babar editor, Pharmaceutical Prices in the 21st Century. London: Springer; 2015. p.\u00a0131\u201351."},{"key":"7255_CR12","unstructured":"Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy. Year 2020. Rome: Italian Medicines Agency; 2021. https:\/\/www.aifa.gov.it\/uso-dei-farmaci-in-italia. Accessed 14 Oct 2021"},{"key":"7255_CR13","doi-asserted-by":"publisher","unstructured":"Harrison J, Mozzicato P. MedDRA\u00ae: The tale of a terminology: Side Effects of Drugs Essay. Side Eff Drugs Annu. 31 2009. doi:https:\/\/doi.org\/10.1016\/S0378-6080(09)03160-2.","DOI":"10.1016\/S0378-6080(09)03160-2"},{"key":"7255_CR14","unstructured":"OSFAR \u2013 Osservatorio Farmaci. Report n. 38- Report Annuale per il 2017. CERGAS \u2013 Universita\u2019 Bocconi. 2018. https:\/\/www.cergas.unibocconi.eu\/sites\/default\/files\/files\/Report38.pdf. Accessed 15 Mar 2021."},{"key":"7255_CR15","unstructured":"Tikkanen R, Wharton G, Djordjevic A, Mossialos E, Williams II RD. The 2020 International Profiles of Healthcare Systems: A Useful Resource for Interpreting Country Responses to the COVID-19 Pandemic. https:\/\/www.commonwealthfund.org\/blog\/2020\/2020-international-profiles-useful-resource-interpreting-responses-covid-19. Accessed 15 Mar 2021."},{"key":"7255_CR16","unstructured":"Regione Lombardia, Prestazioni ambulatoriali \u2013 Open Data. 2021. https:\/\/www.dati.lombardia.it\/Sanit-\/Prestazioni-Ambulatoriali\/d4mg-9zw3. Accessed 1 Dec 2020."},{"key":"7255_CR17","unstructured":"Regione Veneto, Nomenclatore Tariffario Regionale Assistenza Specialistica Ambulatoriale, Allegato B del Decreto di Giunta Regionale n. 47 del 22 Maggio 2013. https:\/\/www.regione.veneto.it\/web\/sanita\/assistenza-ambulatoriale#%22Nomenclatore_tariffario%22. Accessed 1 Dec 2020."},{"key":"7255_CR18","unstructured":"Decreto del Presidente del Consiglio dei Ministri 12 gennaio 2017. Definizione e aggiornamento dei livelli essenziali di assistenza, di cui all\u2019articolo 1, comma 7, del decreto legislativo 30 dicembre 1992, n. 502. (17A02015) (GU Serie Generale n.65 del 18-03-2017 - Suppl. Ordinario n. 15). https:\/\/www.gazzettaufficiale.it\/eli\/id\/2017\/03\/18\/17A02015\/sg. Accessed 15 Mar 2021."},{"key":"7255_CR19","unstructured":"Tariffari nazionali delle prestazioni del Ssn https:\/\/www.salute.gov.it\/portale\/temi\/p2_6.jsp?id=3662&area=programmazioneSanitariaLea&menu=vuoto. Accessed 15 Mar 2021."},{"key":"7255_CR20","unstructured":"Calcolo DRG. http:\/\/www.e-drg.it\/. Accessed 15 Feb 2021."},{"issue":"1","key":"7255_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ajhp\/61.1.27","volume":"61","author":"J LaFleur","year":"2004","unstructured":"LaFleur J, Tyler LS, Sharma RR. Economic benefits of investigational drug services at an academic institution. Am J Health-Syst Pharm. 2004;61(1):27\u201332.","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"7255_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/ajhp\/57.1.40","volume":"57","author":"MS McDonagh","year":"2000","unstructured":"McDonagh MS, Miller SA, Naden E, et al. Costs and savings of investigational drug services. Am J Health-Syst Pharm. 2000;57(1):40\u201343.","journal-title":"Am J Health-Syst Pharm"},{"issue":"2","key":"7255_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.HMR.0000304500.82061.a9","volume":"33","author":"O Uecke","year":"2008","unstructured":"Uecke O, Reszka R, Linke J, Steul M, Posselt T. Clinical trials: considerations for researchers and hospital administrators. Healthcare Manage Rev. 2008;33(2):103\u201312.","journal-title":"Healthcare Manage Rev"},{"issue":"9","key":"7255_CR24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/imj.14302","volume":"49","author":"K Truong","year":"2019","unstructured":"Truong K, Kwan YL, Nigro L, Huseincehajic A, Trotman J, et al. Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology setting. Intern Med J. 2019;49(9): 1092\u20131098.","journal-title":"Intern Med J"},{"issue":"6","key":"7255_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/13696998.2020.1728977","volume":"23","author":"E Walter","year":"2020","unstructured":"Walter E, Eichhober G, Voit M, Baumgartner C, Celedin A, et al. Economic impact of industry sponsored clinical trials of pharmaceutical products in Austria, J Med Econ 2020;23(6):566\u2013574.","journal-title":"J Med Econ"},{"issue":"Suppl 1","key":"7255_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3747\/co.23.2861","volume":"23","author":"PA Tang","year":"2016","unstructured":"Tang PA, Hay AE, O\u2019Callaghan CJ, Mittmann N, Chambers CR, et al. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada. Curr Oncol. 2016;23 Suppl 1:7\u201313.","journal-title":"Curr Oncol"},{"key":"7255_CR27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cct.2010.09.004","volume":"31","author":"C Bredin","year":"2010","unstructured":"Bredin C, Eliasziw M, Syme R. Drug cost avoidance resulting from cancer clinical trials. Contemp Clin Trials. 2010;31:524\u2013529.","journal-title":"Contemp Clin Trials"},{"key":"7255_CR28","first-page":"216","volume":"5","author":"B Jones","year":"2015","unstructured":"Jones B, Eliasziw M, Eigl BJ, Syme R, et al. A comparison of incremental costs of breast cancer clinical trials to standard of care. J Clin Trials. 2015;5:216.","journal-title":"J Clin Trials"},{"key":"7255_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hon.2753","volume":"38","author":"C Herledan","year":"2020","unstructured":"Herledan C, Ranchon F, Schwiertz V, Baudouin A, Karlin L, et al. Drug cost savings in phase III hematological oncology clinical trials in a university hospital. Hematol Oncol. 2020;38:576\u2013583.","journal-title":"Hematol Oncol"},{"key":"7255_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.lungcan.2013.03.021","volume":"81","author":"F Grossi","year":"2013","unstructured":"Grossi F, Genova C, Gaitan ND, Dal Bello MG, Rijavec E, et al. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. Lung Cancer. 2013; 81:236\u2013240.","journal-title":"Lung Cancer"},{"key":"7255_CR31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1186\/s12913-020-05928-6","volume":"20","author":"F D\u2019Ambrosio","year":"2020","unstructured":"D\u2019Ambrosio F, De Feo G, Botti G, Capasso A, Pignata S, et al. Clinical trials and drug cost savings for Italian health service. BMC Health Serv Res. 2020;20:1089.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"7255_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.33393\/grhta.2020.709","volume":"7","author":"A Cicchetti","year":"2020","unstructured":"Cicchetti A, Addesso D, Leone FE, Amato A, Angerame L, et al. Valorization of clinical trials from the Italian National Health Service perspective: definition and first application of a model to estimate avoided costs. Glob Reg Health Technol Assess. 2020;7(1):26\u201332.","journal-title":"Glob Reg Health Technol Assess"},{"key":"7255_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.acuro.2015.05.002","volume":"39","author":"M Calvin-Lamas","year":"2015","unstructured":"Calvin-Lamas M, Portela-Pereira P, Rabu\u00f1al-Alvarez MT, Martinez-Breijo S, Mart\u00edn-Herranz MI, G\u00f3mez-Veiga F. Drug cost avoidance in prostate cancer clinical trials. Actas Urol Esp. 2015;39:553\u2013557.","journal-title":"Actas Urol Esp"},{"issue":"Suppl 1","key":"7255_CR34","first-page":"A91","volume":"25","author":"AM Alamo","year":"2018","unstructured":"Alamo AM, Mateos E, Nucete B, Lujan ME, Lombardero M, Otero C. 4CPS-107 An estimate of avoided costs for drugs in patients included in non-small lung cancer clinical trials. Eur J Hosp Pharm. 2018;25 Suppl 1:A91\u2013A92.","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"7255_CR35","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1177\/1078155218775193","volume":"25","author":"M Ma\u00f1es-Sevilla","year":"2019","unstructured":"Ma\u00f1es-Sevilla M, Romero-Jim\u00e9nez R, Herranz-Alonso A, S\u00e1nchez-Fresneda M, Gonzalez-Haba E, et al. Drug cost avoidance in clinical trials of breast cancer. J Oncol Pharm Pract. 2019;25(5):1099\u20131104.","journal-title":"J Oncol Pharm Pract"},{"key":"7255_CR36","doi-asserted-by":"crossref","unstructured":"Henares L\u00f3pez A, Del R\u00edo Valencia JC, Tamayo Bermejo R, Rosado Souviron MA, Mu\u00f1oz Castillo I. Avoided cost study of drugs in clinical trials at a tertiary hospital. Hospital Regional Universitario de M\u00e1laga, Hospital Pharmacy, M\u00e1laga, Spain. 2020. https:\/\/ejhp.bmj.com\/content\/ejhpharm\/26\/Suppl_1\/A4.2.full.pdf. Accessed 15 Mar 2021.","DOI":"10.1136\/ejhpharm-2019-eahpconf.9"},{"key":"7255_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cct.2011.04.003","volume":"32","author":"LJ Shen","year":"2011","unstructured":"Shen LJ, Chou H, Huang CF, Chou GM, Chan WK, Wu FL. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan. Contemp Clin Trials. 2011;32:485\u2013491.","journal-title":"Contemp Clin Trials."},{"key":"7255_CR38","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.4236\/health.2015.79128","volume":"7","author":"G Ko\u00e7kaya","year":"2015","unstructured":"Ko\u00e7kaya G, Demir M, Kockaya PD, Tatar M, \u00dcresin AY. Economic Impact of Clinical Research to Research Centers and Opportunity Cost for the Reimbursement System in Turkey. Health 2015;7:1124\u20131133.","journal-title":"Health"},{"key":"7255_CR39","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1038\/bjc.2013.495","volume":"109","author":"E Liniker","year":"2013","unstructured":"Liniker E, Harrison M, Weaver JM, Agrawal N, Chhabra A, et al. Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009\u20132010). Br J Cancer. 2013;109:2051\u20132057.","journal-title":"Br J Cancer"},{"key":"7255_CR40","unstructured":"Battelle Technology Partnership Practice. Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies. Ohio; 2015. http:\/\/phrma-docs.phrma.org\/sites\/default\/files\/pdf\/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf. Accessed 15 Mar 2021."},{"issue":"3","key":"7255_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13696998.2019.1678479","volume":"23","author":"D Mladsi","year":"2020","unstructured":"Mladsi D, Hess LM, Barnett CL, Njue A, Huang YJ, et al. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study, J Med Econ. 2020;23(3):213\u2013220.","journal-title":"J Med Econ"},{"key":"7255_CR42","unstructured":"Regione Veneto - Gruppo Farmaci Innovativi del Coordinamento della Rete Oncologica Veneta (ed.), Raccomandazione n. 31 Carcinoma polmonare non a piccole cellule per la chinasi del linfoma anaplastico (ALK+) I linea. July 2020. Annex A of Regional Decree no. 80\/2020. https:\/\/www.regione.veneto.it\/documents\/10793\/1016153\/Decreto+del+Direttore+Generale+Area+Sanit%C3\u2009%A0+e+Sociale+n.+80+del+04.08.2020.pdf\/4df293b2-d41d-4b95-9c18-00c4a3594b18. Accessed 15 Mar 2021."},{"key":"7255_CR43","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge R, Shaw AT, Gadgeel S, Ahn, JS, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2017;377:829\u201338.","journal-title":"N Engl J Med"},{"key":"7255_CR44","unstructured":"Regione Veneto - Gruppo Farmaci Innovativi del Coordinamento della Rete Oncologica Veneta. Raccomandazione n. 32 Carcinoma polmonare non a piccole cellule per la chinasi del linfoma anaplastico (ALK+) II linea. July 2020. Annex A of Regional Decree no. 81\/2020. https:\/\/www.regione.veneto.it\/documents\/10793\/1016153\/Decreto+del+Direttore+Generale+Area+Sanit%C3\u2009%A0+e+Sociale+n.+81+del+04.08.2020.pdf\/d5ef89ee-2a13-4f76-86ef-8a796b852e04. Accessed 15 Mar 2021."},{"issue":"6","key":"7255_CR45","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S, Mazi\u00e8res J, Oh I-J, de Castro J, Migliorino MR, Helland \u00c5, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409\u201316.","journal-title":"Ann Oncol"},{"key":"7255_CR46","unstructured":"Regione Veneto - Gruppo Farmaci Innovativi del Coordinamento della Rete Oncologica Veneta. Raccomandazione n. 13 Pemetrexed - Alimta\u00ae, Allegato C al Decreto n. 253 del 28 agosto 2015. https:\/\/salute.regione.veneto.it\/c\/document_library\/get_file?uuid=8d73e93f-d9d2-4c4a-a67d-2d3c280df78d&groupId=534936. Accessed 15 Mar 2021."},{"key":"7255_CR47","unstructured":"AIFA. Regime di rimborsabilita\u2019 e prezzo di vendita del medicinale \u00abDocetaxel Teva\u00bb (docetaxel) autorizzata con procedura centralizzata europea. Determinazione 18th November 2010 (10A14171) GU Serie Generale n.283 del 03-12-2010. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2010\/12\/03\/10A14171\/sg. Accessed 15 Mar 2021."},{"key":"7255_CR48","doi-asserted-by":"crossref","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, Loriot Y, Vogelzang NJ, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748\u201357.","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"7255_CR49","unstructured":"AIFA, Regime di rimborsabilit\u00e0 e prezzo del medicinale \u00abOpdivo\u00bb. Determina no. 1403\/2018. GU Serie Generale n. 224 del 26.09.18. https:\/\/www.medicoeleggi.com\/argomenti000\/italia2018\/410465.html. Accessed 15 Mar 2021."},{"key":"7255_CR50","unstructured":"Regione Toscana \u2013 Commissione Terapeutica Regionale Atezolizumab (TECENTRIQ\u2122). 1 ottobre 2018. https:\/\/www.regione.toscana.it\/documents\/10180\/15552024\/SchedaTecentriq-atezolizumab.pdf\/7dfe2062-4eb7-4bce-b065-107d2a27b664. Accessed 15 Mar 2021."},{"key":"7255_CR51","unstructured":"AIFA. Determina 15 settembre 2020 Rinegoziazione del medicinale per uso umano \u00abAvastin\u00bb ai sensidell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. DG\/934\/2020). (20A05115) (GU n.238 del 25-9-2020). https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/Determina-DG-934-2020_Avastin.pdf."},{"key":"7255_CR52","first-page":"259","volume":"8","author":"A Russo","year":"2017","unstructured":"Russo A, Priolo D, Antonelli G, Libra M, McCubrey JA, Ferrau F. Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer (Auckl). 2017;8:259\u2013269.","journal-title":"Lung Cancer (Auckl)"},{"key":"7255_CR53","unstructured":"AIFA. Regime di rimborsabilita\u2019 e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano \u00abAbraxane\u00bb (paclitaxel-albumina). Determina no. 57\/2015 (15A00779). GU Gazzetta Ufficiale Serie Generale n.30 del 06-02-2015 https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2015-02-06&atto.codiceRedazionale=15A00779&elenco30giorni=false. Accessed 15 Mar 2021."},{"key":"7255_CR54","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1136\/esmoopen-2019-000504","volume":"4","author":"R Caparica","year":"2019","unstructured":"Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer. ESMO Open. 2019;4:e504.","journal-title":"ESMO Open"},{"key":"7255_CR55","unstructured":"Regione Veneto - Gruppo Farmaci Innovativi del Coordinamento della Rete Oncologica Veneta. Raccomandazione n. 25 Anticorpi ANTI-PD-1 e BRAF inibitore\/MEK inibitore - melanoma inoperabile o metastatico (Decreto n. 91 del 25 luglio 2017). https:\/\/www.regione.veneto.it\/web\/sanita\/raccomandazioni-farmaci-oncologici. Accessed 15 Mar 2021."},{"key":"7255_CR56","unstructured":"AIFA. Regime di rimborsabilita\u2019 e prezzo di vendita del medicinale per uso umano \u00abZelboraf (vemurafenib)\u00bb, autorizzata con procedura centralizzata europea dalla Commissione europea. Determina n. 500\/2013 (13A04712). GU Serie Generale n.129 del 04-06-2013 https:\/\/www.gazzettaufficiale.it\/eli\/id\/2013\/06\/04\/13A04712\/sg. Accessed 15 Mar 2021."},{"key":"7255_CR57","unstructured":"Regione Toscana \u2013 Commissione Terapeutica Regionale. Ocrelizumab (Ocrevus). 5th November 2018. https:\/\/www.regione.toscana.it\/documents\/10180\/15552024\/Scheda+Ocrevus-Ocrelizumab.pdf\/04e2a03f-b8d7-4573-803e-199a2704a13f. Accessed 15 Mar 2021."},{"key":"7255_CR58","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al. B-Cell Depletion with Rituximab in Relapsing\u2013Remitting Multiple Sclerosis. N Engl J Med. 2008;358:676\u201388.","journal-title":"N Engl J Med"},{"key":"7255_CR59","unstructured":"AIFA. Inserimento del medicinale Bendamustina nell\u2019elenco dei medicinali erogabili a totale carico del Servizio sanitario nazionale ai sensi della legge 23 dicembre 1996, n. 648, per il trattamento del linfoma diffuso a grandi cellule B primitivo o trasformato da forme a basso grado, recidivato\/refrattario (\u22652 linee di terapia), in combinazione con rituximab con o senza citarabina. Determina n. 3390\/2020). (20A00467), GU Serie Generale n.20 del 25-01-2020. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2020-01-25&atto.codiceRedazionale=20A00467&elenco30giorni=false. Accessed 15 Mar 2021."},{"key":"7255_CR60","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2019","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019;38:155\u2013165.","journal-title":"J Clin Oncol"},{"key":"7255_CR61","unstructured":"AIFA. Regime di rimborsabilita\u2019 e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano \u00abRevlimid\u00bb. Determina no 753\/2018 (18A03533), https:\/\/www.aifa.gov.it\/documents\/20142\/241028\/Determina_753-2018_Revlimid.pdf\/c054c839-c9a9-a7f5-05b6-698fe7be6a9e. Accessed 15 Mar 2021."},{"issue":"15","key":"7255_CR62","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","volume":"23","author":"MS Czuczman","year":"2017","unstructured":"Czuczman MS, Trn\u011bn\u00fd M, Davies A, Rule S, Linton KM, et al. A Phase 2\/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator\u2019s Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2017;23(15):4127\u20134137.","journal-title":"Clin Cancer Res"},{"key":"7255_CR63","unstructured":"Magnano R. Sma, cos\u00ec una terapia innovativa diventa \u00abbuona sanit\u00e0\u00bb. Sanita\u2019 24. 2018. https:\/\/www.sanita24.ilsole24ore.com\/art\/dal-governo\/2018-03-14\/sma-cosi-terapia-innovativa-diventa-buona-sanita-124808.php?uuid=AE88jlGE. Accessed 15 Mar 2021."},{"key":"7255_CR64","unstructured":"Regione Veneto - Gruppo Farmaci Innovativi del Coordinamento della Rete Oncologica Veneta. Raccomandazione n. 2 Trastuzumab Emtansine Kadcyla\u00ae, Annex B of Regional Decree no. 119\/2015. https:\/\/www.regione.veneto.it\/c\/document_library\/get_file?uuid=e687fa0b-4080-4cef-b101-0477c2190f93&groupId=10793. Accessed 15 Mar 2021."},{"key":"7255_CR65","unstructured":"IQVIA. EFPIA Patients W.A.I.T. Indicator 2019 Survey May 2020. 2020. https:\/\/www.efpia.eu\/publications\/downloads\/efpia\/efpia-patients-wait-indicator-2019-survey\/. Accessed 15 Mar 2021."},{"issue":"1","key":"7255_CR66","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clinthera.2019.11.006","volume":"42","author":"C Jommi","year":"2020","unstructured":"Jommi C, Armeni P, Costa F, Bertolani A, Otto M. Implementation of Value-based Pricing for Medicines. Clin Ther. 2020;42(1):15\u201324.","journal-title":"Clin Ther"},{"key":"7255_CR67","doi-asserted-by":"crossref","unstructured":"Ravasio R, Tiseo M, Pradelli L, Bellone M, Gervasi A, Coffani M. Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer, Glob Reg Health Technol Assess. 2019:1\u201311.","DOI":"10.33393\/grhta.2019.462"},{"key":"7255_CR68","unstructured":"AIFA, Farmaci ad uso compassionevole. https:\/\/www.aifa.gov.it\/farmaci-a-uso-compassionevole. Accessed 14 Oct 2021."},{"key":"7255_CR69","unstructured":"AIFA. Riclassificazione del medicinale per uso umano \u00abBendamustina Accord\u00bb ai sensi dell\u2019articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. Determina no. 730\/2016 (16A04416), GU Serie Generale n.137 del 14-06-2016. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2016\/06\/14\/16A04416\/sg. Accessed 15 Mar 2021."},{"key":"7255_CR70","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00277-018-3317-6","volume":"97","author":"JY Hong","year":"2018","unstructured":"Hong JY, Yoon DH, Suh C, Kim WS, Kim SJ, et al. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. Ann Hematol. 2018;97:1437\u20131443.","journal-title":"Ann Hematol"},{"key":"7255_CR71","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O\u2019Brien S, et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017;34:2232\u20132273.","journal-title":"Adv Ther"},{"key":"7255_CR72","unstructured":"Roche Registration GmbH. Annex I \u2013 Summary Product Characteristics. In: European Medicines Agency. Avastin: EPAR \u2013 Product Information (20\/01\/2021 Avastin - EMEA\/H\/C\/000582 - IB\/0119). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/avastin-epar-product-information_en.pdf. Accessed 15 Mar 2021."},{"key":"7255_CR73","unstructured":"AIFA. Regime di rimborsabilita\u2019 e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano \u00abKeytruda\u00bb. Determina no. 1764\/2019. (19A07665). GU Serie Generale n.290 del 11-12-2019. https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/Determina_1764-2019_Keytruda_ca.uroteliale.pdf\/29fdd26e-28aa-24b8-84e7-fa3539397d38. Accessed 15 Mar 2021."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07255-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-021-07255-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-07255-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T11:29:46Z","timestamp":1699874986000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-07255-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7255"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-07255-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-678616\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"2 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not require ethics approval and consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is not needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CJ received research grants from Abbvie, Alnylam, Amgen, Astrazeneca, Bayer, BMS,\u00a0Boehringer I, Celgene, EuroQoL Foundation, FSK, Gilead, Janssen C, MSD, Novartis, Roche, Pfizer, Sandoz, Sanofi, Takeda, Teva for his research activity and acted as a speaker and or consultant for Amgen, Astrazeneca, BMS, Celgene, CSL Behring, Dephaforum, Gilead, Incyte, MA Provider, MSD, Roche, Sanofi, Takeda, Wellmera (now Alira Health).\u00a0FP and LS are employed by Roche Italy.\u00a0MC received research grants from Amgen, Novartis and Roche for her research activity.\u00a0MV declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1303"}}